Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis

被引:14
|
作者
Topp, Max S. [1 ]
Stein, Anthony S. [2 ]
Goekbuget, Nicola [3 ]
Horst, Heinz-August [4 ]
Boissel, Nicolas [5 ]
Martinelli, Giovanni [6 ]
Kantarjian, Hagop [7 ]
Brueggemann, Monika [8 ]
Chen, Yuqi [9 ]
Zugmaier, Gerhard [10 ]
机构
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] City Hope Med Ctr, Gehr Leukemia Ctr, Duarte, CA USA
[3] Univ Klinikum, Med Klin Hamatol Onkol Rheumatol Infektiol 3, Frankfurt, Germany
[4] Univ Klinikum Schleswig Holstein, Klin Innere Med 2, Kiel, Germany
[5] Hop St Louis, Unite Hematol Adolescents & Jeunes Adultes, Paris, France
[6] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Sci Directorate, Meldola, FC, Italy
[7] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[8] Univ Klinikum Schleswig Holstein, Sekt Hamatol Spezialdiagnost, Klin Innere Med 2, Kiel, Germany
[9] Amgen Inc, Global Biostat Sci, Thousand Oaks, CA 91320 USA
[10] Amgen Res Munich GmbH, Global Dev, Munich, Germany
来源
CANCER MEDICINE | 2021年 / 10卷 / 08期
关键词
acute lymphoblastic leukemia; BiTE® blinatumomab; salvage; stem cell transplant;
D O I
10.1002/cam4.3731
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Blinatumomab is a BiTE(R) immuno-oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). To assess the efficacy and safety of blinatumomab as first salvage versus second or later salvage in patients with r/r BCP ALL. Patient-level pooled data were used for this analysis. In total, 532 adults with r/r BCP ALL treated with blinatumomab were included (first salvage, n = 165; second or later salvage, n = 367). Compared with patients who received blinatumomab as second or later salvage, those who received blinatumomab as first salvage had a longer median overall survival (OS; 10.4 vs. 5.7 months; HR, 1.58; 95% CI, 1.26-1.97; P < .001) and relapse-free survival (10.1 vs. 7.3 months; HR, 1.38; 95% CI, 0.98-1.93; P = .061), and higher rates of remission (n = 89 [54%] vs. n = 150 [41%]; odds ratio, 0.59; 95% CI, 0.41-0.85; P = .005), minimal residual disease response (n = 68 [41%] vs. n = 118 [32%]), and allogeneic hematopoietic stem cell transplant (alloHSCT) realization (n = 60 [36%] vs. n = 88 [24%]), and alloHSCT in continuous remission (n = 33 [20%] vs. n = 52 (14%]). In a subgroup analysis, there was no apparent effect of prior alloHSCT on median OS in either salvage group. The safety profile of blinatumomab was generally similar between the groups; however, cytokine release syndrome, febrile neutropenia, and infection were more frequent with second or later salvage than with first salvage. In this pooled analysis, the logistic regression analyses indicated greater benefit with blinatumomab as first salvage than as second or later salvage, as evident by the longer median OS, longer median RFS, and higher rates of remission. Overall, blinatumomab was beneficial as first salvage and as second or later salvage, but the effects were favorable as first salvage. Aims Materials & Methods Results Discussion Conclusion
引用
收藏
页码:2601 / 2610
页数:10
相关论文
共 50 条
  • [31] Reduced-Intensity Chemotherapy Plus Inotuzumab Ozogamicin, With or Without Sequential Blinatumomab, is Highly Effective as First Salvage Treatment in Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
    Short, Nicholas
    Jabbour, Elias
    Sasaki, Koji
    Ravandi, Farhad
    Huang, Xuelin
    Kebriaei, Partow
    Jain, Nitin
    Garcia-Manero, Guillermo
    Kadia, Tapan
    Konopleva, Marina
    Jacob, Jovitta
    Garris, Rebecca
    Cortes, Jorge
    O'Brien, Susan
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S186 - S187
  • [32] Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
    Queudeville, Manon
    Stein, Anthony S.
    Locatelli, Franco
    Ebinger, Martin
    Handgretinger, Rupert
    Goekbuget, Nicola
    Gore, Lia
    Zeng, Yi
    Gokani, Priya
    Zugmaier, Gerhard
    Kantarjian, Hagop M.
    CANCER, 2023, 129 (09) : 1384 - 1393
  • [33] BUDGET IMPACT ANALYSIS OF BLINATUMOMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO
    Alva, M. E.
    Ortiz, M.
    Flores, B.
    VALUE IN HEALTH, 2018, 21 : S27 - S27
  • [34] Superior Survival Outcome of Blinatumomab Compared to Mitoxantrone-Etoposide-Cytarabine Salvage for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: A Propensity Score-Matched Cohort Analysis
    Yoon, Jae-Ho
    Min, Gi June
    Park, Sung-Soo
    Park, Silvia
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Min, Chang-Ki
    Cho, Seok-Goo
    Lee, Jong Wook
    Lee, Seok
    BLOOD, 2021, 138
  • [35] Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia:: results of a prospective trial
    Martino, R
    Bellido, M
    Brunet, S
    Altés, A
    Sureda, A
    Guárdia, R
    Aventín, A
    Nomedéu, JF
    Domingo-Albós, A
    Sierra, J
    HAEMATOLOGICA, 1999, 84 (06) : 505 - 510
  • [36] Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective
    Delea, Thomas E.
    Amdahl, Jordan
    Boyko, Diana
    Hagiwara, May
    Zimmerman, Zachary F.
    Franklin, Janet L.
    Cong, Ze
    Hechmati, Guy
    Stein, Anthony
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (09) : 911 - 922
  • [37] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE NETHERLANDS
    van Oostrum, I
    De Lameillieure, K.
    Russell-Smith, T. A.
    VALUE IN HEALTH, 2020, 23 : S444 - S444
  • [38] Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
    Locatelli, Franco
    Zugmaier, Gerhard
    Mergen, Noemi
    Bader, Peter
    Jeha, Sima
    Schlegel, Paul-Gerhardt
    Bourquin, Jean-Pierre
    Handgretinger, Rupert
    Brethon, Benoit
    Roessig, Claudia
    Kormany, William N.
    Viswagnachar, Puneeth
    Chen-Santel, Christiane
    BLOOD ADVANCES, 2022, 6 (03) : 1004 - 1014
  • [39] BUDGET IMPACT ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Encheva-Malinova, M.
    Pavlova, Y.
    Varbanova, V.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S26 - S26
  • [40] Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia
    J. L. Fuster
    F. Bautista
    B. González
    J. M. Fernández
    S. Rives
    J. L. Dapena
    Clinical and Translational Oncology, 2021, 23 : 1963 - 1966